<DOC>
	<DOC>NCT03052725</DOC>
	<brief_summary>This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.</brief_summary>
	<brief_title>A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<criteria>• Patient with eosinophilic asthma who completed the treatment period of a doubleblind, placebo controlled sc reslizumab study (Study C38072AS30025 or C38072AS30027) ~~ Additional criteria apply, please contact the investigator for more information Patient has received any reslizumab administration in any previous clinical trial other than Studies C38072AS30025 and C38072AS30027. The patient has any clinically significant, uncontrolled medical condition The patient has another confounding underlying lung disorder The patient has a known/diagnosed hypereosinophilic syndrome. The patient has a diagnosis of malignancy within 5 years of the screening visit, except for treated and cured nonmelanoma skin cancers. The patient is a pregnant or lactating woman The patient is a current smoker (ie, has smoked within the last 6 months before screening) or has a smoking history ≥10 packyears. The patient is currently using any systemic immunosuppressive or immunomodulatory agents other than OCS The patient has a history of allergic reaction or hypersensitivity to any component of the study drug. The patient has a history of an immunodeficiency disorder including human immunodeficiency virus (HIV). Additional criteria apply, please contact the investigator for more information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>